前列腺癌检测中，外周带T2信号强度指数（PZ_Si2）对PI-RADS v2.1≥3病灶的PCa和CsPCa检测AUC分别为0.89和0.86，最优阈值≤5.25可减少42 ...

本研究针对基于白人群体开发的PI-RADS评分系统在非白人群体中的适用性问题，通过分析PREVENT试验中665例PI-RADS 3-5分患者的活检数据，发现黑人男性PI-RADS 3分病灶的临床显著前列腺癌(csPCa)检出率较白人高20%(OR 1.20, P=0.004)，而亚洲男性PI-RADS 3分病灶均未检出癌症。

Upgrade and downgrade rates from targeted biopsy to radical prostatectomy were not significantly different between patients whose MRI examinations were clinically interpreted using PI-RADS Version ...

Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial.

Temporal trends and factors associated with overuse of neoadjuvant androgen deprivation therapy in low and very low risk prostate cancer. Changes in multiparametric prostate MRI and immune subsets in ...

Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management TEL AVIV, Israel & SAN JOSE, ...

Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis. Combining PSA density (PSAD) with prostate magnetic ...